Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on December 6, 2024. The report addresses a regulatory notice regarding the continued listing of the Company's common stock on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the status of the Company's stock listing.
Material Changes
On December 6, 2024, the Company received a written notice from Nasdaq stating that its Common Stock failed to meet the minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This determination was based on the closing bid price for the last 30 consecutive business days. Consequently, an automatic 180-calendar-day grace period has been initiated.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has until June 4, 2025, to regain compliance. Compliance is achieved if the bid price closes at or above $1.00 per share for a minimum of 10 consecutive business days.
- Trading Status: The notice has no immediate effect on trading; the stock will continue to trade under the symbol "CYCC."
- Delisting Risk: If compliance is not met within the grace period (including any potential extensions), Nasdaq will notify the Company that the stock is subject to delisting. The Company may appeal such a determination.
- Management Action: The Company intends to monitor bid prices and is considering alternatives to achieve compliance, including a potential reverse stock split. Management notes there can be no assurance that compliance will be achieved.
Investor Verification Checklist
- Verify the current closing bid price of CYCC common stock relative to the $1.00 threshold.
- Monitor official announcements regarding the potential execution of a reverse stock split.
- Track the 180-day compliance deadline ending June 4, 2025.
- Review future filings for updates on the Company's progress toward regaining compliance or any appeals filed with Nasdaq.